Preserved Activity of CD20-Specific Chimeric Antigen Receptor–Expressing T Cells in the Presence of Rituximab

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer immunology research

• Publication date

  2016-04-21

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/2326-6066.CIR-15-0276PMID 27197068PMCID PMC4891234
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia

  2015cited by this paper
• Target Antigen Density Governs the Efficacy of Anti–CD20-CD28-CD3 ζ Chimeric Antigen Receptor–Modified Effector CD8+ T Cells

  2015cited by this paper
• Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor.

  2015cited by this paper
• T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial.

  2015influential reference
• The Nonsignaling Extracellular Spacer Domain of Chimeric Antigen Receptors Is Decisive for In Vivo Antitumor Activity

  2014cited by this paper
• Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma

  2013cited by this paper
• Receptor Affinity and Extracellular Domain Modifications Affect Tumor Recognition by ROR1-Specific Chimeric Antigen Receptor T Cells

  2013cited by this paper
• Chimeric antigen receptor-modified T cells for acute lymphoid leukemia.

  2013cited by this paper
• CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

  2013cited by this paper
• Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia.

  2013cited by this paper
• CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results.

  2012cited by this paper
• CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.

  2011cited by this paper
• CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.

  2011cited by this paper
• T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia

  2011cited by this paper
• Preclinical correction of human Fanconi anemia complementation group A bone marrow cells using a safety-modified lentiviral vector

  2010cited by this paper
• Adoptive immunotherapy with genetically engineered T cells: modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response

  2010cited by this paper
• The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum

  2009cited by this paper
• Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20.

  2009cited by this paper
• Antibody-mediated B-cell depletion before adoptive immunotherapy with T cells expressing CD20-specific chimeric T-cell receptors facilitates eradication of leukemia in immunocompetent mice.

  2009cited by this paper
• Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.

  2008cited by this paper
• Phase III study of R-CVP compared with cyclophosphamide, vincristine, and prednisone alone in patients with previously untreated advanced follicular lymphoma.

  2008cited by this paper
• Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

  2008cited by this paper
• Antigen Sensitivity of CD22-Specific Chimeric TCR Is Modulated by Target Epitope Distance from the Cell Membrane1

  2008cited by this paper
• Optimizing Adoptive Polyclonal T Cell Immunotherapy of Lymphomas, Using a Chimeric T Cell Receptor Possessing CD28 and CD137 Costimulatory Domains

  2007cited by this paper
• Development of a new fully human anti-CD20 monoclonal antibody for the treatment of B-cell malignancies

  2007cited by this paper
• Rituximab blocks binding of radiolabeled anti-CD20 antibodies (Ab) but not radiolabeled anti-CD45 Ab.

  2007cited by this paper
• The Biological Activity of Human CD20 Monoclonal Antibodies Is Linked to Unique Epitopes on CD201

  2006cited by this paper
• T cells armed with anti-CD3 x anti-CD20 bispecific antibody enhance killing of CD20+ malignant B cells and bypass complement-mediated rituximab resistance in vitro.

  2005cited by this paper
• Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa

  2005cited by this paper
• Characterization of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin lymphomas.

  2004cited by this paper
• Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.

  2004cited by this paper
• The mitogen-induced increase in T cell size involves PKC and NFAT activation of Rel/NF-kappaB-dependent c-myc expression.

  2004cited by this paper
• Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.

  2003cited by this paper
• Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.

  2003cited by this paper
• CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

  2002cited by this paper
• CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.

  2002cited by this paper
• Alanine-170 and proline-172 are critical determinants for extracellular CD20 epitopes; heterogeneity in the fine specificity of CD20 monoclonal antibodies is defined by additional requirements imposed by both amino acid sequence and quaternary structure.

  2002cited by this paper
• T cell activation by recombinant FcepsilonRI gamma-chain immune receptors: an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition.

  2000cited by this paper
• Efficient Discrimination between Different Densities of Target Antigen by Tetracycline-Regulatable T Bodies

  1999cited by this paper
• Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.

  1999cited by this paper
• CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.

  1998cited by this paper
• A chimeric receptor that selectively targets membrane-bound carcinoembryonic antigen (mCEA) in the presence of soluble CEA

  1998cited by this paper
• IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma.

  1997cited by this paper
• Retention of B-cell-specific monoclonal antibodies by human lymphoma cells.

  1994cited by this paper
• Modulation and intracellular transport of CD20 and CD21 antigens induced by B1 and B2 monoclonal antibodies in RAJI and JOK-1 cells--an immunofluorescence and immunoelectron microscopy study.

  1994cited by this paper
• Antibody-induced modulation and intracellular transport of CD10 and CD19 antigens in human B-cell lines: an immunofluorescence and immunoelectron microscopy study.

  1993cited by this paper
• Monoclonal antibody 1F5 (anti-CD20) serotherapy of human B cell lymphomas.

  1987cited by this paper

• ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-Hodgkin lymphoma

  2024cites this paper
• CD20 CAR T-cells safely and reversibly ablate B-cell follicles in a nonhuman primate model of HIV persistence.

  2024cites this paper
• Alternative splicing of its 5′-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

  2023cites this paper
• PGE2-EP2/EP4 signaling elicits mesoCAR T cell immunosuppression in pancreatic cancer

  2023cites this paper
• Alternative splicing of its 5’-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

  2023cites this paper
• Chimeric Antigen Receptor T-cell Therapy for Chronic Lymphocytic Leukemia: What is the supporting evidence so far?

  2023cites this paper
• Chimeric antigen receptor engineered T-cell therapy for central nervous system lymphoma

  2022cites this paper
• Rational protein design yields a CD20 CAR with superior antitumor efficacy compared to CD19 CAR.

  2022cites this paper
• CD20-specific chimeric antigen receptor-expressing T cells as salvage therapy in rituximab-refractory/relapsed B-cell non-Hodgkin lymphoma.

  2022cites this paper
• CAR-T cell Therapies for B-cell Lymphoid Malignancies: Identifying Targets Beyond CD19.

  2022cites this paper
• Current Status and Perspectives of Dual-Targeting Chimeric Antigen Receptor T-Cell Therapy for the Treatment of Hematological Malignancies

  2022cites this paper
• Pre-clinical efficacy of CD20-targeted chimeric antigen receptor T cells for non-Hodgkin's lymphoma

  2022cites this paper
• VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding

  2021cites this paper
• The “Magic Bullet” Is Here? Cell-Based Immunotherapies for Hematological Malignancies in the Twilight of the Chemotherapy Era

  2021cites this paper
• Anti-CD19 CARs displayed at the surface of lentiviral vector particles promote transduction of target-expressing cells

  2021cites this paper
• Additional possibilities of chimeric antigen receptor T-cells in B-cell lymphoma: combination therapy

  2020cites this paper
• Potentials, challenges and future of chimeric antigen receptor T-cell therapy in non-Hodgkin lymphomas

  2020cites this paper
• Pharmacological targeting of immune checkpoint A2aR improves function of anti-CD19 CAR T cells in vitro.

  2020cites this paper
• Construction and Functional Characterization of a Fully Human Anti-mesothelin Chimeric Antigen Receptor (CAR) Expressing T Cell.

  2020cites this paper
• Rational Tuning of CAR Tonic Signaling Yields Superior T-Cell Therapy for Cancer

  2020cites this paper
• A Novel Method to Construct Dual-targeted Magnetic Nanoprobes by Modular Assembling

  2020cites this paper
• A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy

  2019cites this paper
• An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma.

  2018cites this paper
• Preclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions

  2018cites this paper
• Construction and functional characterization of a fully human anti‐CD19 chimeric antigen receptor (huCAR)‐expressing primary human T cells

  2018cites this paper
• CAR T Cells with Enhanced Sensitivity to B Cell Maturation Antigen for the Targeting of B Cell Non-Hodgkin's Lymphoma and Multiple Myeloma.

  2018cites this paper
• Desensitized chimeric antigen receptor T cells selectively recognize target cells with enhanced antigen expression

  2018cites this paper
• The acceleration of CAR‐T therapy in non‐Hodgkin lymphoma

  2018cites this paper
• T cell modulation in immunotherapy for hematological malignancies

  2017cites this paper
• CD20-based Immunotherapy of B-cell Derived Hematologic Malignancies.

  2017cites this paper
• Tales of Antigen Evasion from CAR Therapy

  2016cites this paper